Trial Profile
Effect of roflumilast on exacerbation rate in patients with chronic obstructive pulmonary disease. A 52 weeks double blind study with 500mcg roflumilast once daily versus placebo. RATIO-study.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 02 Dec 2016
Price :
$35
*
At a glance
- Drugs Roflumilast (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Registrational; Therapeutic Use
- Acronyms RATIO
- 15 Jul 2007 Results have been published
- 01 Mar 2007 New trial record.